RLX Technology reported Q1 2026 results this morning that should, on paper, impress: revenue surged to $229.9 million from $111.4 million a year ago, while adjusted EPS climbed to $0.04 from $0.03. The stock fell 3.2% on the day regardless. That gap between the numbers and the reaction is the whole story this week.
The disconnect makes more sense when you look at where the stock has come from and what the market is paying for it now. The PE ratio has drifted to around 13.6x, a compression of roughly half a turn over the past month, while EV/EBITDA has edged lower to 7.4x. Price-to-book has slipped to just above 1x. These are not expensive multiples for a company doubling its top line — but they reflect the structural discount that has shadowed RLX since China's regulatory crackdown on e-vapor products. Analysts carry a mean price target of around $2.50, close enough to the $2.10 close price that there is no compelling valuation gap in play. The one outlier reading — a headline figure citing far higher consensus targets in prior notes — appears to reflect stale data from pre-downgrade coverage and should be discounted. The most recent analyst action on record, a Citigroup note from March maintaining Neutral at $2.50, told a simple story: the revenue recovery is real, but the regulatory ceiling is real too.
The EPS surprise factor score ranks in the 97th percentile, and dividend momentum scores even higher. The forward yield is running near 7.3% — an unusually large carry for a $2.6 billion market-cap Chinese ADR. EPS momentum at both 30 and 90-day horizons sits solidly above the median. These are quality signals pointing at a cash-generative business. They are also signals that the market has been aware of and is apparently still discounting, given the YTD decline of nearly 10%.
Positioning in the borrow market tells an easy story: shorts are not the problem here. Borrow availability is essentially uncapped — the lending pool dwarfs short demand by orders of magnitude, with availability per unit of short interest sitting at the system ceiling. Cost to borrow is a negligible 0.53%, and has been erratic rather than trending, having touched 2.05% on May 6 before falling back sharply. Short interest, at roughly 4.4 million shares, has crept up about 13% over the past month, but in the context of a $2.6 billion float, that addition is barely a rounding error. The ORTEX short score of 29 confirms the same reading: below-average bearish conviction. Options lean more constructive, with the put/call ratio at 0.17 — below its 20-day average of 0.21, and running close to the lower end of the past year's range. Call activity is dominating options flow, suggesting at least a subset of the market had been positioning for today's earnings print.
Among correlated peers, the week was a different story. PM added 2.5% on the week and MO gained 5.9%, with both benefiting from the broader defensive tone in tobacco. BATS also rose 5.8%. RLX's 2.8% weekly decline runs in the opposite direction — a reminder that the company trades on Chinese regulatory sentiment as much as it does on sector flows, and those two forces rarely move together.
Q1 revenue more than doubled and the stock went down. That divergence — a company outperforming operationally while the valuation refuses to re-rate — is the watch item. The next catalyst to track is any signal from Beijing on e-cigarette enforcement timelines, which remains the one variable that quarterly numbers alone cannot resolve.
See the live data behind this article on ORTEX.
Open RLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
